Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery systems.

The objective of this research was to determine the binding capacity and kinetics, and total incorporation of recombinant human bone morphogenetic protein-2 (rhBMP-2) in microspheres made from hydrophilic and hydrophobic poly(lactide-co-glycolide) (PLGA). Polymers were characterized by molecular weight, polydispersity, and acid number. Microspheres were produced via a water-in-oil-in-water double emulsion system and characterized for bulk density, size, specific surface area, and porosity. Protein concentrations were determined by reversed phase HPLC. Protein was loaded by soaking microspheres in a buffered solution, pH 4.5, of rhBMP-2, decanting excess liquid, and vacuum drying the wetted particles. Total loading and binding were determined by comparing protein concentration remaining to non-microsphere containing samples. Polymer acid number was the dominant polymer feature affecting the binding. Higher acid values correlated with increased rhBMP-2 binding. The amount of non-bound incorporated rhBMP-2 linearly correlated with the concentration of protein used in binding. High rhBMP-2 concentrations inhibit binding to PLGA microspheres. Binding was also inhibited by increased lactide content in the PLGA polymer. The polymer characteristics controlling rhBMP-2 binding to PLGA microspheres are acid value foremost followed by molecular weight and lactide/glycolide ratio. The total amount of rhBMP-2 incorporated depends on the bound amount and on the amount of free protein present.

[1]  V. Goldberg,et al.  Ectopic induction of cartilage and bone by water-soluble proteins from bovine bone using a polyanhydride delivery vehicle. , 1989, Journal of biomedical materials research.

[2]  C. Kirker-Head,et al.  Bone formation in the goat maxillary sinus induced by absorbable collagen sponge implants impregnated with recombinant human bone morphogenetic protein-2. , 1996, The International journal of periodontics & restorative dentistry.

[3]  A. Hickey,et al.  Prednisolone-21 -acetate poly(glycolic acid) microspheres: Influence of matrix characteristics on release☆ , 1989 .

[4]  I. Ishikawa,et al.  Periodontal regeneration by application of recombinant human bone morphogenetic protein-2 to horizontal circumferential defects created by experimental periodontitis in beagle dogs. , 1997, Journal of periodontology.

[5]  J. Wozney,et al.  Periodontal repair in dogs: recombinant human bone morphogenetic protein-2 significantly enhances periodontal regeneration. , 1995, Journal of periodontology.

[6]  Jian-Hwa Guo Preparation Methods of Biodegradable Microspheres on Bovine Serum Albumin Loading Efficiency and Release Profiles , 1994 .

[7]  E. Fu,et al.  Bone morphogenetic protein-2 for peri-implant bone regeneration and osseointegration. , 1997, Clinical oral implants research.

[8]  R. Mehta,et al.  Biodegradable microspheres as depot system for patenteral delivery of peptide drugs , 1994 .

[9]  S. Lynch,et al.  Effects of the platelet-derived growth factor/insulin-like growth factor-I combination on bone regeneration around titanium dental implants. Results of a pilot study in beagle dogs. , 1991, Journal of periodontology.

[10]  R. Mehta,et al.  Effect of processing parameters on the properties of peptide-containing PLGA microspheres. , 1997, Journal of microencapsulation.

[11]  R. Marx,et al.  A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. , 1997, The International journal of periodontics & restorative dentistry.

[12]  J. Hollinger,et al.  Osseous regeneration in the rat calvarium using novel delivery systems for recombinant human bone morphogenetic protein-2 (rhBMP-2). , 1994, Journal of biomedical materials research.

[13]  R. Delamarter,et al.  Effective Doses of Recombinant Human Bone Morphogenetic Protein‐2 in Experimental Spinal Fusion , 1996, Spine.

[14]  R. Mehta,et al.  Interaction of recombinant human bone morphogenetic protein-2 with poly(d,l lactide-co-glycolide) microspheres. , 1996, Pharmaceutical development and technology.

[15]  E. Wang,et al.  Long-term healing of bone using recombinant human bone morphogenetic protein 2. , 1995, Clinical orthopaedics and related research.

[16]  A. Shahzamani,et al.  A month–long effect from a single injection of microencapsulated human growth hormone , 1996, Nature Medicine.

[17]  P. Giunchedi,et al.  Solvent evaporation, solvent extraction and spray drying for polylactide microsphere preparation , 1992 .

[18]  J M Toth,et al.  Experimental Spinal Fusion With Recombinant Human Bone Morphogenetic Protein-2 Without Decortication of Osseous Elements , 1997, Spine.

[19]  S. Boden,et al.  Biologic Enhancement of Spinal Fusion , 1995, The Orthopedic clinics of North America.

[20]  J. Michael Kabo,et al.  Evaluation of rhBMP‐2 With an OPLA Carrier in a Canine Posterolateral (Transverse Process) Spinal Fusion Model , 1995, Spine.

[21]  T. Uchida,et al.  Preparation and characterization of polylactic acid microspheres containing water-soluble dyes using a novel w/o/w emulsion solvent evaporation method. , 1996, Journal of microencapsulation.

[22]  J. Fiorellini,et al.  A feasibility study evaluating rhBMP-2/absorbable collagen sponge device for local alveolar ridge preservation or augmentation. , 1997, The International journal of periodontics & restorative dentistry.

[23]  P. P. Deluca,et al.  The evaluation of lyophilized polymer matrices for administering recombinant human bone morphogenetic protein-2. , 1996, Pharmaceutical development and technology.